Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30964328 | 0.91 | GRIN2D (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30964326 | 0.88 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30512699 | 0.85 | GRIN2D (0.52) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29800882 | 0.84 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29827042 | 0.84 | BACE1 (0.44) | RXFP1BACE1TASP1 | |
| Gigiltvil SCHEMBL30741431 | 0.84 | CTSD (0.46) | RENCTSD | |
| SCHEMBL38656413 | 0.84 | TASP1 (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL31462106 | 0.83 | CTSB (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30570971 | 0.83 | GRIN2D (0.55) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30437164 | 0.83 | RXFP1 (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115874-A1 | Compositions And Methods For Making And Using Atherosclerotic Nanomatrix Vascular Sheets | UAB RESEARCH FOUNDATION | 2025-04-10 | — | — | US | disclosed |
| US-20240218017-A1 | PEPTIDE AMPHIPHILES WITH MODIFIED DEGRADING SEQUENCES AND METHODS OF USE THEREOF | Endomimetics LLC | 2024-07-04 | — | — | US | disclosed |
| US-20240199698-A1 | PEPTIDE AMPHIPHILE COMPOSITIONS AND METHODS OF USE THEREOF | Endomimetics LLC | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218017-A1 | PEPTIDE AMPHIPHILES WITH MODIFIED DEGRADING SEQUENCES AND METHODS OF USE THEREOF | ABHD16A, LIPG, POLQ | GRIN2D 2735/4885GRIN3B 1595/4885GRIN1 1805/4885 |
| US-20240199698-A1 | PEPTIDE AMPHIPHILE COMPOSITIONS AND METHODS OF USE THEREOF | PLD4, NGLY1, VIP | GRIN2D 1679/4885GRIN3B 690/4885GRIN1 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.